Research and Technology Mydecine’s research strategy hinges on identifying and developing novel psychedelic and non-psychedelic molecules for medical use. Using molecules found in nature as building blocks to produce second-generation drugs, the company’s R&D efforts focus on compounds that may enable safer, more effective treatments for patients, as well as providing clinicians with better management of dosage and drug behavior. Through an exclusive partnership with Applied Pharmaceutical Innovation and the University of Alberta, Mydecine leverages the benefits of artificial intelligence and machine learning (AI/ML). The university’s faculty of pharmacologists is currently ranked in the top 15 in the world for pharmaceutical drug discovery, and top three in the world for artificial intelligence. Using AI/ML, the team can screen billions of compounds rapidly without the need to produce them, and can immediately collect data on viable drug candidates prior to further investment in development. By centering drug discovery efforts on AI/ML, Mydecine is positioned to discover drug enhancements cost effectively and efficiently. The University of Alberta partnership brings an extraordinarily strong depth of experience in pharmaceutical and natural products chemistry, and also allows the company to complete all production for its clinical trials. Mydecine’s pipeline currently consists of drug candidates that provide various enhancements such as improved delivery mechanisms, safety, controllability, stability and shelf-life. These drug candidates are part of psychedelic-assisted therapy programs and are in clinical trials or pre-trial stages as potential treatments for smoking cessation and PTSD. Mydecine’s clinical trial highlights include a five-year research agreement with Johns Hopkins University, one of the most experienced academic institutions in conducting clinical research related to psychedelic therapies.
RkJQdWJsaXNoZXIy NDMyMDk=